1-20 of 124
Julio Rosenstock
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Achieving Normoglycemia With Tirzepatide: Analysis of SURPASS 1–4 Trials

Julio Rosenstock, Luis Vázquez, Stefano Del Prato, Denise Reis Franco, Govinda Weerakkody, Biyue Dai, Laura Fernández Landó, Brandon K. Bergman, Angel Rodríguez
Journal: Diabetes Care
Diabetes Care 2023;46(11):1986–1992
https://doi.org/10.2337/dc23-0872
Published: 06 September 2023
View article titled, Achieving Normoglycemia With Tirzepatide: Analysis of SURPASS 1–4 Trials
Open the PDF for Achieving Normoglycemia With Tirzepatide: Analysis of SURPASS 1–4 Trials in another window
Journal Articles

Effects of Semaglutide on Albuminuria and Kidney Function in People With Overweight or Obesity With or Without Type 2 Diabetes: Exploratory Analysis From the STEP 1, 2, and 3 Trials

Hiddo J.L. Heerspink, Ellen Apperloo, Melanie Davies, Dror Dicker, Kristian Kandler, Julio Rosenstock, Rasmus Sørrig, Jack Lawson, Niels Zeuthen, David Cherney
Journal: Diabetes Care
Diabetes Care 2023;46(4):801–810
https://doi.org/10.2337/dc22-1889
Published: 17 February 2023
View article titled, Effects of Semaglutide on Albuminuria and Kidney Function in People With Overweight or Obesity With or Without Type 2 Diabetes: Exploratory Analysis From the STEP 1, 2, and 3 Trials
Open the PDF for Effects of Semaglutide on Albuminuria and Kidney Function in People With Overweight or Obesity With or Without Type 2 Diabetes: Exploratory Analysis From the STEP 1, 2, and 3 Trials in another window
Journal Articles

Efficacy and Safety of Once-Weekly Efpeglenatide Monotherapy Versus Placebo in Type 2 Diabetes: The AMPLITUDE-M Randomized Controlled Trial

Juan Pablo Frias, JaeDuk Choi, Julio Rosenstock, Luiza Popescu, Elisabeth Niemoeller, Isabel Muehlen-Bartmer, Seungjae Baek
Journal: Diabetes Care
Diabetes Care 2022;45(7):1592–1600
https://doi.org/10.2337/dc21-2656
Published: 06 July 2022
View article titled, Efficacy and Safety of Once-Weekly Efpeglenatide Monotherapy Versus Placebo in Type 2 Diabetes: The AMPLITUDE-M Randomized Controlled Trial
Open the PDF for Efficacy and Safety of Once-Weekly Efpeglenatide Monotherapy Versus Placebo in Type 2 Diabetes: The AMPLITUDE-M Randomized Controlled Trial in another window
Journal Articles

Editorial Cycles and Continuity of Diabetes Care

Matthew C. Riddle, with and on behalf of Associate Editors Vanita Aroda, George Bakris, Lawrence Blonde, Andrew J.M. Boulton, Jessica Castle, Linda DiMeglio, Linda Gonder-Frederick, Frank Hu, Steven Kahn, Sanjay Kaul, Robert Moses, Stephen Rich, Julio Rosenstock, Elizabeth Selvin, Adrian Vella, Judith Wylie-Rosett
Journal: Diabetes Care
Diabetes Care 2022;45(7):1493–1494
https://doi.org/10.2337/dci22-0020
Published: 06 July 2022
View article titled, Editorial Cycles and Continuity of <em>Diabetes Care</em>
Open the PDF for Editorial Cycles and Continuity of <em>Diabetes Care</em> in another window
Journal Articles

Response to Comment on Rosenstock et al. Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial. Diabetes Care 2020;43:2509–2518

Julio Rosenstock
Journal: Diabetes Care
Diabetes Care 2021;44(11):e196–e197
https://doi.org/10.2337/dci21-0004
Published: 18 October 2021
View article titled, Response to Comment on Rosenstock et al. Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial. Diabetes Care 2020;43:2509–2518
Open the PDF for Response to Comment on Rosenstock et al. Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial. Diabetes Care 2020;43:2509–2518 in another window
Journal Articles

Advancing Therapy in Suboptimally Controlled Basal Insulin–Treated Type 2 Diabetes: Clinical Outcomes With iGlarLixi Versus Premix BIAsp 30 in the SoliMix Randomized Controlled Trial

Julio Rosenstock, Rifat Emral, Leobardo Sauque-Reyna, Viswanathan Mohan, Carlos Trescolí, Saud Al Sifri, Nebojsa Lalic, Agustina Alvarez, Pascaline Picard, Mireille Bonnemaire, Nacima Demil, Rory J. McCrimmon
Journal: Diabetes Care
Diabetes Care 2021;44(10):2361–2370
https://doi.org/10.2337/dc21-0393
Published: 06 August 2021
View article titled, Advancing Therapy in Suboptimally Controlled Basal Insulin–Treated Type 2 Diabetes: Clinical Outcomes With iGlarLixi Versus Premix BIAsp 30 in the SoliMix Randomized Controlled Trial
Open the PDF for Advancing Therapy in Suboptimally Controlled Basal Insulin–Treated Type 2 Diabetes: Clinical Outcomes With iGlarLixi Versus Premix BIAsp 30 in the SoliMix Randomized Controlled Trial in another window
Journal Articles

Response to Comment on Ferrannini and Rosenstock. Clinical Translation of Cardiovascular Outcome Trials in Type 2 Diabetes: Is There More or Is There Less Than Meets the Eye? Diabetes Care 2021;44:641–646

Ele Ferrannini, Julio Rosenstock
Journal: Diabetes Care
Diabetes Care 2021;44(7):e155
https://doi.org/10.2337/dci21-0014
Published: 20 July 2021
View article titled, Response to Comment on Ferrannini and Rosenstock. Clinical Translation of Cardiovascular Outcome Trials in Type 2 Diabetes: Is There More or Is There Less Than Meets the Eye? Diabetes Care 2021;44:641–646
Open the PDF for Response to Comment on Ferrannini and Rosenstock. Clinical Translation of Cardiovascular Outcome Trials in Type 2 Diabetes: Is There More or Is There Less Than Meets the Eye? Diabetes Care 2021;44:641–646 in another window
Journal Articles

Erratum. Clinical Translation of Cardiovascular Outcome Trials in Type 2 Diabetes: Is There More or Is There Less Than Meets the Eye? Diabetes Care 2021;44: 641–646

Ele Ferrannini, Julio Rosenstock
Journal: Diabetes Care
Diabetes Care 2021;44(6):1454
https://doi.org/10.2337/dc21-er06
Published: 23 April 2021
View article titled, Erratum. Clinical Translation of Cardiovascular Outcome Trials in Type 2 Diabetes: Is There More or Is There Less Than Meets the Eye? Diabetes Care 2021;44: 641–646
Open the PDF for Erratum. Clinical Translation of Cardiovascular Outcome Trials in Type 2 Diabetes: Is There More or Is There Less Than Meets the Eye? Diabetes Care 2021;44: 641–646 in another window
Journal Articles

A Randomized, Open-Label Comparison of Once-Weekly Insulin Icodec Titration Strategies Versus Once-Daily Insulin Glargine U100

Ildiko Lingvay, John B. Buse, Edward Franek, Melissa V. Hansen, Mette M. Koefoed, Chantal Mathieu, Jeremy Pettus, Karolina Stachlewska, Julio Rosenstock
Journal: Diabetes Care
Diabetes Care 2021;44(7):1595–1603
https://doi.org/10.2337/dc20-2878
Published: 19 April 2021
View article titled, A Randomized, Open-Label Comparison of Once-Weekly Insulin Icodec Titration Strategies Versus Once-Daily Insulin Glargine U100
Open the PDF for A Randomized, Open-Label Comparison of Once-Weekly Insulin Icodec Titration Strategies Versus Once-Daily Insulin Glargine U100 in another window
Journal Articles

Switching to Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Type 2 Diabetes Inadequately Controlled on Daily Basal Insulin: A Phase 2 Randomized Controlled Trial

Harpreet S. Bajaj, Richard M. Bergenstal, Andreas Christoffersen, Melanie J. Davies, Amoolya Gowda, Joakim Isendahl, Ildiko Lingvay, Peter A. Senior, Robert J. Silver, Roberto Trevisan, Julio Rosenstock
Journal: Diabetes Care
Diabetes Care 2021;44(7):1586–1594
https://doi.org/10.2337/dc20-2877
Published: 19 March 2021
View article titled, Switching to Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Type 2 Diabetes Inadequately Controlled on Daily Basal Insulin: A Phase 2 Randomized Controlled Trial
Open the PDF for Switching to Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Type 2 Diabetes Inadequately Controlled on Daily Basal Insulin: A Phase 2 Randomized Controlled Trial in another window
Journal Articles

Clinical Translation of Cardiovascular Outcome Trials in Type 2 Diabetes: Is There More or Is There Less Than Meets the Eye?

Ele Ferrannini, Julio Rosenstock
Journal: Diabetes Care
Diabetes Care 2021;44(3):641–646
https://doi.org/10.2337/dc20-0913
Published: 11 February 2021
View article titled, Clinical Translation of Cardiovascular Outcome Trials in Type 2 Diabetes: Is There More or Is There Less Than Meets the Eye?
Open the PDF for Clinical Translation of Cardiovascular Outcome Trials in Type 2 Diabetes: Is There More or Is There Less Than Meets the Eye? in another window
Journal Articles

Durable Effects of iGlarLixi Up to 52 Weeks in Type 2 Diabetes: The LixiLan-G Extension Study

Lawrence Blonde, Julio Rosenstock, Juan Frias, Andreas L. Birkenfeld, Elisabeth Niemoeller, Elisabeth Souhami, Chen Ji, Stefano Del Prato, Vanita R. Aroda
Journal: Diabetes Care
Diabetes Care 2021;44(3):774–780
https://doi.org/10.2337/dc20-2023
Published: 19 January 2021
View article titled, Durable Effects of iGlarLixi Up to 52 Weeks in Type 2 Diabetes: The LixiLan-G Extension Study
Open the PDF for Durable Effects of iGlarLixi Up to 52 Weeks in Type 2 Diabetes: The LixiLan-G Extension Study in another window
Journal Articles

A Lesson From 2020: Public Health Matters for Both COVID-19 and Diabetes

Matthew C. Riddle, George Bakris, Lawrence Blonde, Andrew J.M. Boulton, David D’Alessio, Linda A. DiMeglio, Linda Gonder-Frederick, Korey K. Hood, Frank B. Hu, Steven E. Kahn, Sanjay Kaul, Lawrence A. Leiter, Robert G. Moses, Stephen S. Rich, Julio Rosenstock, Judith Wylie-Rosett
Journal: Diabetes Care
Diabetes Care 2021;44(1):8–10
https://doi.org/10.2337/dci20-0071
Published: 14 December 2020
View article titled, A Lesson From 2020: Public Health Matters for Both COVID-19 and Diabetes
Open the PDF for A Lesson From 2020: Public Health Matters for Both COVID-19 and Diabetes in another window
Journal Articles

Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial

Julio Rosenstock, Antonio Nino, Joseph Soffer, Lois Erskine, Andre Acusta, Jo Dole, Molly C. Carr, Jason Mallory, Philip Home
Journal: Diabetes Care
Diabetes Care 2020;43(10):2509–2518
https://doi.org/10.2337/dc19-2316
Published: 21 July 2020
View article titled, Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial
Open the PDF for Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial in another window
Journal Articles

Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial

Vlado Perkovic, Robert Toto, Mark E. Cooper, Johannes F.E. Mann, Julio Rosenstock, Darren K. McGuire, Steven E. Kahn, Nikolaus Marx, John H. Alexander, Bernard Zinman, Egon Pfarr, Sven Schnaidt, Thomas Meinicke, Maximillian von Eynatten, Jyothis T. George, Odd Erik Johansen, Christoph Wanner
Journal: Diabetes Care
Diabetes Care 2020;43(8):1803–1812
https://doi.org/10.2337/dc20-0279
Published: 22 May 2020
View article titled, Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial
Open the PDF for Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial in another window
Journal Articles

Efficacy and Safety of the Glucagon Receptor Antagonist RVT-1502 in Type 2 Diabetes Uncontrolled on Metformin Monotherapy: A 12-Week Dose-Ranging Study

Jeremy H. Pettus, David D’Alessio, Juan P. Frias, Eric G. Vajda, James D. Pipkin, Julio Rosenstock, Gretchen Williamson, Miriam A. Zangmeister, Lin Zhi, Keith B. Marschke
Journal: Diabetes Care
Diabetes Care 2020;43(1):161–168
https://doi.org/10.2337/dc19-1328
Published: 06 November 2019
View article titled, Efficacy and Safety of the Glucagon Receptor Antagonist RVT-1502 in Type 2 Diabetes Uncontrolled on Metformin Monotherapy: A 12-Week Dose-Ranging Study
Open the PDF for Efficacy and Safety of the Glucagon Receptor Antagonist RVT-1502 in Type 2 Diabetes Uncontrolled on Metformin Monotherapy: A 12-Week Dose-Ranging Study in another window
Includes: Supplementary data
Journal Articles

Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial

Helena W. Rodbard, Julio Rosenstock, Luis H. Canani, Chaicharn Deerochanawong, Janusz Gumprecht, Søren Østergaard Lindberg, Ildiko Lingvay, Anette Luther Søndergaard, Marianne Bach Treppendahl, Eduard Montanya, PIONEER 2 Investigators, Pablo Cruz, Luis De Loredo, Cecilia Luquez, Maria Moisello, Gustavo Akerman Augusto, Marise Castro, Luis Canani, Branko Akrap, Tomislav Bulum, Dario Rahelic, Ivana Sunic-Grcic, Srecko Tusek, Iakovos Avramidis, Marian Benroubi, Triantafyllos Didangelos, Gerasimos Karousos, Emmanouil Pagkalos, Christos Sampanis, Maria Somali, Zsolt Domboróczki, Péter Faludi, Zsolt Gaál, Piroska Kis-Gombos, Gyozo Kocsis, Zoltán Marton, Zsolt Sudár, Silvio Buscemi, Alberto Di Carlo, Francesco Dotta, Alessandra Gambineri, Davide Lauro, Marianna Maranghi, Malgorzata Arciszewska, Janusz Gumprecht, Krystyna Matuszewska, Ewa Skokowska, Teresa Stasinska, Svetlana Feofanova, Ekaterina Filippova, Gagik Galstyan, Leylya Gaysina, Marina Kunitsyna, Lyudmila Suplotova, Slobodan Antic, Aleksandar Djukic, Milena Mitrovic, Milica Pesic, Edita Stokic, Esteban Jodar, Encarna Martínez, Pedro Mezquita Raya, Eduard Montanya, Cristobal Morales Portillo, Mercè Pérez Vera, Margarita Rivas Fernández, Patricia San Jose, Manel Terns Riera, Apussanee Boonyavarakul, Chaicharn Deerochanawong, Apiradee Sriwijitkamol, Dilawar Ajani, Eddie Armas, Kim Barbel-Johnson, Darlene Bartilucci, Gholamreza Bonabi, Robert Busch, David Butuk, Kevin Cannon, Craig Chase, Louis Chaykin, Vasundhara Cheekati, Thomas Davis, Belkis Delgado, Neil Farris, Mark Graves, Chi Ha, Linda Harper, Sharon Herring, Mitzie Hewitt, Daniel Hsia, Richard Jackson, Michael Jardula, Mark Joyce, Mario Juarez, Anoop Kapoor, Dennis Karounos, David Kayne, Audrey Lacour, Gilbert Ledesma, Ildiko Lingvay, Robert Lipetz, Joseph Lomboy, Sean Lynd, Emily Morawski, Robert Morin, Richard Murphy, J. Scott Overcash, John Pullman, Helena W. Rodbard, Julio Rosenstock, Gary Ruoff, Devin Steenkamp, Hugo Toro, David Trachtenbarg, Brian Tulloch, Albert Weisbrot, Alison Wright
Journal: Diabetes Care
Diabetes Care 2019;42(12):2272–2281
https://doi.org/10.2337/dc19-0883
Published: 07 October 2019
View article titled, Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial
Open the PDF for Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial in another window
Includes: Supplementary data
Journal Articles

Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical Trial

Lawrence Blonde, Julio Rosenstock, Stefano Del Prato, Robert Henry, Naim Shehadeh, Juan Frias, Elisabeth Niemoeller, Elisabeth Souhami, Chen Ji, Vanita R. Aroda
Journal: Diabetes Care
Diabetes Care 2019;42(11):2108–2116
https://doi.org/10.2337/dc19-1357
Published: 17 September 2019
View article titled, Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical Trial
Open the PDF for Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical Trial in another window
Includes: Supplementary data
Journal Articles

Once-Weekly Efpeglenatide Dose-Range Effects on Glycemic Control and Body Weight in Patients With Type 2 Diabetes on Metformin or Drug Naive, Referenced to Liraglutide

Julio Rosenstock, Christopher H. Sorli, Michael E. Trautmann, Cristóbal Morales, Ulrich Wendisch, George Dailey, Marcus Hompesch, In Young Choi, Jahoon Kang, John Stewart, Kun-Ho Yoon
Journal: Diabetes Care
Diabetes Care 2019;42(9):1733–1741
https://doi.org/10.2337/dc18-2648
Published: 12 August 2019
View article titled, Once-Weekly Efpeglenatide Dose-Range Effects on Glycemic Control and Body Weight in Patients With Type 2 Diabetes on Metformin or Drug Naive, Referenced to Liraglutide
Open the PDF for Once-Weekly Efpeglenatide Dose-Range Effects on Glycemic Control and Body Weight in Patients With Type 2 Diabetes on Metformin or Drug Naive, Referenced to Liraglutide in another window
Includes: Supplementary data
Journal Articles

Effect of Linagliptin on Cognitive Performance in Patients With Type 2 Diabetes and Cardiorenal Comorbidities: The CARMELINA Randomized Trial

Geert Jan Biessels, Chloë Verhagen, Jolien Janssen, Esther van den Berg, Bernard Zinman, Julio Rosenstock, Jyothis T. George, Anna Passera, Sven Schnaidt, Odd Erik Johansen
Journal: Diabetes Care
Diabetes Care 2019;42(10):1930–1938
https://doi.org/10.2337/dc19-0783
Published: 09 August 2019
View article titled, Effect of Linagliptin on Cognitive Performance in Patients With Type 2 Diabetes and Cardiorenal Comorbidities: The CARMELINA Randomized Trial
Open the PDF for Effect of Linagliptin on Cognitive Performance in Patients With Type 2 Diabetes and Cardiorenal Comorbidities: The CARMELINA Randomized Trial in another window
Includes: Supplementary data